Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-H1-0, (131)I-chTNT-1/B Vector   (CAT#: GTVCR-WQ22MR)

This product GTVCR-WQ22MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting H1-0. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Chimeric
RefSeq NM_005318.4
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 3005
UniProt ID P07305
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-H1-0, (131)I-chTNT-1/B Vector (GTVCR-WQ22MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1989MR IVTScrip™ pSP6-VEE-mRNA-Anti-GUCY2C, MLN-0264 Vector Vector MLN-0264
GTVCR-WQ1122MR IVTScrip™ pSP6-VEE-mRNA-Anti-MUC16, DMUC5754A Vector Vector DMUC5754A
GTVCR-WQ1073MR IVTScrip™ pSP6-VEE-mRNA-Anti-Factor IX substitute, CSL654 Vector Vector CSL654
GTVCR-WQ2050MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD274, MPDL3280A Vector Vector MPDL3280A
GTVCR-WQ1468MR IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF4, IBI-101 Vector Vector IBI-101
GTVCR-WQ1618MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957 Vector Vector JNJ-64007957
GTVCR-WQ2519MR IVTScrip™ pT7-VEE-mRNA-Anti-KDR, SSS-23 Vector Vector SSS-23
GTVCR-WQ2654MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD19, XmAb5871 Vector Vector XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW